In numerous cancer cell lines, oncogenic PI3K activation has indeed recently been shown to be mediated not by AKT but by SGK3, another kinase that activates mTORC1 [41], suggesting that AKT itself may be only one of several relevant targets for antileukemic interventions targeting the PI3K pathway. Here, SGK3 is linked to cancer.